Principal Investigator
Byron Lam
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20241031
Clinical Trial Summary
A Phase 1b Open-label Study to Evaluate the Pharmacokinetics,
Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects with Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety,Tolerability, and Efficacy of Tinlarebant in Subjects with Stargardt Disease
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other